TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03322540

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered orally twice daily.
Study: NCT03066505

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active MeRT Treatment
Description: A personalized biometrics-guided protocol known as magnetic EEG/EKG resonance therapy (MeRT) treatment that is tailored specifically to each patient's higher harmonic frequency of heart rate, which is nearest to the characteristic frequency of alpha EEG frequency.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham MeRT Treatment
Description: A personalized biometrics-guided protocol similar to MeRT treatment that mimics magnetic EEG/EKG resonance therapy (MeRT) but does not emit active stimulation.
Study: NCT03281239

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Laser doppler, blood tests, and holter ECG
Description: Diagnostic tests :~* laser doppler~* blood tests~* Holter ECG. No drug and no placebo were used in this arm.
Study: NCT03024944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-THK-5351
Description: Intravenous (IV) catheter (tube) placed in participant arm. A small amount of 18F-THK-5351 will be injected into the IV enough time has passed for this contrast to collect in the tissue in the brain (approximately one half-hour), and participant will lie on a bed which slides into a PET Scanner to complete Tau imaging.
Study: NCT00757354

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metal on Metal cementless hip
Description: Metal on Metal hip arthroplasty
Study: NCT02616172

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Infusion
Description: The subjects autologous bone marrow cells harvested at Florida Hospital will be infused intravenously by gravity
Study: NCT04014127

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary flow reserve assessment
Description: Coronary flow reserve will be assessed using Doppler transthoracic echocardiograpy and myocardial contrast echocardiography.
Study: NCT04613284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human endostatin (Endostar)
Description: Continuous intravenous infusion of endostar (Simcere Pharma- ceutical, Nanjing, China) was made over 120 h before the begin- ning of radiotherapy, and then repeated every two weeks. The dose was 7.5 mg/m2/24 h 120 h, 14 days/cycle. ECG monitoring was performed during the first delivery of endostar.
Study: NCT04014127

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary flow reserve assessment
Description: Coronary flow reserve will be assessed using Doppler transthoracic echocardiograpy and myocardial contrast echocardiography.

Intervention type: DIAGNOSTIC_TEST
Intervention: Sphygmocor
Description: Pulse wave analysis and pulse wave velocity will be assessed using the Sphygmocor device

Intervention type: DIAGNOSTIC_TEST
Intervention: Sphygmocor
Description: Pulse wave analysis and pulse wave velocity will be assessed using the Sphygmocor device

Intervention type: DIAGNOSTIC_TEST
Intervention: Sphygmocor
Description: Pulse wave analysis and pulse wave velocity will be assessed using the Sphygmocor device
Study: NCT04613284

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic irradiation of 50 Gy with 3DCRT or IMRT
Description: Concurrent thoracic chemoradiotherapy with reduced irradiation dose of 50 Gy will be given to patients with unresectable stage III NSCLC who can not tolerate irradiation dose to 60 Gy.
Study: NCT04630119

Intervention type: OTHER
Intervention: Questionnaires on quality of life, emotional health and presenteeism
Description: After obtaining informed consent, a pro forma consisting of the socio-demographic details and pre-treatment assessment questionnaire (including Visual analog scale The Medical Outcomes Study Short-Form Health Survey The hospital anxiety and depression scale Work functioning impairment scale) was filled for each subject.
Study: NCT00487240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro Protamine Suspension
Description: Patient specific dose, twice daily (BID), within 15 minutes before meals, subcutaneous (SC) injection x 32 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Levemir
Description: Patient specific dose insulin Levemir (detemir) twice daily (BID) subcutaneous (SC) injection x 32 weeks
Study: NCT02560961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping (Kinesio Tex Gold®; color: black)
Description: Kinesio Taping technique described by Kase for activation of the triceps surae on the dominant leg will be employed, with the volunteer in the prone position, maintaining the dominant leg off the cot with hip extension, knee extension and ankle dorsiflexion to maintain the triceps surae in a stretched position. The tape will be applied in a Y shape beginning with the origin of the muscle (femur condyles) without tension (Anchor I), passing over the belly of the muscle (therapeutic region) with 15 to 20% tension and ending near the posterior surface of the heel (Anchor II) without tension.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Taping
Description: Standard white bandaging tape will be applied by the same researcher who placed the tape in Group A. The application will be performed the same way as a kinesio taping.
Study: NCT01221402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended-release niacin (Niaspan)
Description: Patients will be randomized in a 1:1 ratio to receive extended-release niacin (1500 - 2000 mg per day) or matching placebo that contains 50 mg of crystalline niacin (enough to cause flushing but has no effect on lipid levels).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: extended-release niacin (Niaspan)
Description: Patients will be randomized in a 1:1 ratio to receive extended-release niacin (1500 - 2000 mg per day) or matching placebo that contains 50 mg of crystalline niacin (enough to cause flushing but has no effect on lipid levels).
Study: NCT00240994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Administered intravenously over a period of 2-3 hours. Two doses total, the first will be one day before transplant and the second will be on the day following transplantation. Pre-medication with methylprednisolone, acetaminophen, and Benadryl will be administered before each dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Administered orally at a dose of 0.05-0.1 mg/kg twice daily, beginning 1-3 days following transplantation and continuing until weeks 8-12. Tacrolimus will be discontinued and a treatment regimen with sirolimus will be initiated between weeks 8-12 but some overlap with these medications is possible.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Per recommendation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Administered by either liquid or tablet every 12 hours from month 6 until month 24. Dosage will vary throughout the treatment course.
Study: NCT02353507

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Opticell Ag+

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aquacel Ag+
Study: NCT03063021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl Cysteine (NAC)
Description: Oral tablets of N-acetyl-cysteine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl Cysteine (NAC)
Description: Oral tablets of N-acetyl-cysteine
Study: NCT04014127

Intervention type: DIAGNOSTIC_TEST
Intervention: Sphygmocor
Description: Pulse wave analysis and pulse wave velocity will be assessed using the Sphygmocor device

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram
Description: An electrocardiogram will be performed prior to administration of adenosine to ensure no resting conduction disease

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram
Description: An electrocardiogram will be performed prior to administration of adenosine to ensure no resting conduction disease

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram
Description: An electrocardiogram will be performed prior to administration of adenosine to ensure no resting conduction disease

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram
Description: An electrocardiogram will be performed prior to administration of adenosine to ensure no resting conduction disease

Intervention type: OTHER
Intervention: Blood test
Description: Blood tests will be performed for markers of renal function, bone mineral metabolism and myocardial stretch and injury

Intervention type: OTHER
Intervention: Blood test
Description: Blood tests will be performed for markers of renal function, bone mineral metabolism and myocardial stretch and injury

Intervention type: OTHER
Intervention: Blood test
Description: Blood tests will be performed for markers of renal function, bone mineral metabolism and myocardial stretch and injury

Intervention type: OTHER
Intervention: Blood test
Description: Blood tests will be performed for markers of renal function, bone mineral metabolism and myocardial stretch and injury

Intervention type: OTHER
Intervention: Urinary albumin/creatinine ratio
Description: Urine will be analysed for albumin/creatinine ratio

Intervention type: OTHER
Intervention: Urinary albumin/creatinine ratio
Description: Urine will be analysed for albumin/creatinine ratio

Intervention type: OTHER
Intervention: Urinary albumin/creatinine ratio
Description: Urine will be analysed for albumin/creatinine ratio

Intervention type: OTHER
Intervention: Urinary albumin/creatinine ratio
Description: Urine will be analysed for albumin/creatinine ratio
Study: NCT01017640

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02495493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction DCS chemotherapy
Description: docetaxel /cisplatin/S-1 followed by chemoradiotherapy (S-1/cisplatin)
Study: NCT00795288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin, 80 mg/day for 21 days
Description: Active treatment group
Study: NCT01246310

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inositol

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02596737

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: wittyFit concept
Study: NCT01428583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxycodone HCl and naltrexone HCl extended-release capsules
Description: Daily dose range of 20 mg to 160 mg of the oxycodone component in a 24 hour time interval, administered twice daily approximately 12 hours apart (At the discretion of the Investigator, oxycodone HCl and naltrexone HCl extended-release capsules may be administered once daily, at 24 hour intervals.)
Study: NCT02370524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]T807
Description: All enrolled subjects will undergo an \[18F\]T807 PET imaging visit. In addition, subjects with AD and aged volunteers will have one PET scan with Amyvid (florbetapir F 18 injection) as part of the screening activities to measure Aβ in the brain.
Study: NCT01504997

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot assisted distal gastrectomy (DaVinci)
Description: patients who received robot assisted distal gastrectomy
Study: NCT03473015

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICSO
Description: The PICSO Impulse catheter is a 8F double lumen catheter with a 15.5x20mm long balloon at the distal end. The balloon inflates and deflates cyclically once deployed in the coronary sinus, leading to intermitted coronary sinus pressure increase. The catheter is connected to the console through two pneumatic tubes in which helium is shuttled to and from the balloon. In addition, the coronary sinus pressure is monitored through the center lumen of the catheter.
Study: NCT01799837

Intervention type: DRUG
Group type: OTHER
Intervention: [C-11]MENET
Description: PET imaging involves injecting small amounts of a radioactive material into the blood stream. The radioactive material is attached to a drug called MENET that will give information about how the brain interacts with a protein called norepinephrine (NE).

Intervention type: DRUG
Group type: OTHER
Intervention: [C-11]MENET
Description: PET imaging involves injecting small amounts of a radioactive material into the blood stream. The radioactive material is attached to a drug called MENET that will give information about how the brain interacts with a protein called norepinephrine (NE).
Study: NCT02499484

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glyceryl trinitrate
Description: Topical GTN will be used daily in combination with a eccentric home exercise program

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ointment
Description: Topical placebo ointment will be used in combination with a eccentric home exercise program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric exercise program
Description: All participants will complete the eccentric exercise program as a home exercise program daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Eccentric exercise program
Description: All participants will complete the eccentric exercise program as a home exercise program daily.
Study: NCT03377257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolmitriptan by sublingual administration
Description: Experimental group
Study: NCT02445404

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP
Description: cyclophosphamide, 750mg/m² IV day1 doxorubicin, 50 mg/m² IV day1 vincristine, 1.4 mg/m² (max 2 mg) IV day1 prednisone ,40 mg/m² PO day1\~5 every 3 weeks
Study: NCT03377257

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zolmitriptan by oral
Description: Active group
Study: NCT00599053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 10 mg/kg IV per dose given for 10 days
Study: NCT02445404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP
Description: cyclophosphamide, 750mg/m² IV day1 doxorubicin, 50 mg/m² IV day1 vincristine, 1.4 mg/m² (max 2 mg) IV day1 prednisone ,40 mg/m² PO day1\~5 every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fractionated ICED
Description: ifosfamide, 1.67 g/m² IV day1\~3 carboplatin, AUC =5 IV day1 etoposide, 100mg/m² IV day1\~3 dexamethasone 40 mg PO or IV day1\~4 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fractionated ICED
Description: ifosfamide, 1.67 g/m² IV day1\~3 carboplatin, AUC =5 IV day1 etoposide, 100mg/m² IV day1\~3 dexamethasone 40 mg PO or IV day1\~4 every 3 weeks
Study: NCT04037072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: Topical application of Mytomycin C (MMC)
Study: NCT03994822

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Thrombectomy using the pRESET Thrombectomy device
Description: Clot removal using the pRESET Thrombectomy device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Thrombectomy using the Solitaire Revascularization Device
Description: Clot removal using the Solitaire Revascularization Device
Study: NCT00703872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral HDV-Interferon + ribavarin
Description: Naive pateints

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injectable HDV-Interferon + ribavarin
Description: Nonresponders
Study: NCT03281759

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial LED Therapy (Active coil helmet)
Description: The patients will undergo 18 sessions of repetitive transcranial LED stimulation.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial LED Therapy (Inactive coil helmet)
Description: The patients assigned to this group will undergo 18 sessions of transcranial LED but with an inactive coil, which will not generate LED emissions, only a similar red light color.
Study: NCT04477070

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Air-polishing with ultrasonic debridement
Description: Use of air-polishing and ultrasonic device (Airflow Prophylaxis Master, EMS, Nyon, Switzerland) to remove plaque and calculus from the surface of the roots of teeth.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional scaling and root planing
Description: Use of scaling instruments to remove plaque and calculus from the surface of the roots of teeth.
Study: NCT01960335

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Protein
Description: Whey protein provided in 20 gram servings administered three times per day. once in the morning upon waking; a second serving in the mid-afternoon; and a third serving within 2 hours of going to sleep at night.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein
Description: Whey protein provided in 20 gram servings administered three times per day. once in the morning upon waking; a second serving in the mid-afternoon; and a third serving within 2 hours of going to sleep at night.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein
Description: Whey protein provided in 20 gram servings administered three times per day. once in the morning upon waking; a second serving in the mid-afternoon; and a third serving within 2 hours of going to sleep at night.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein and Resistance Exericse
Description: Subjects will receive 20 grams of whey protein three times per day along with 4 days per week of resistance exercise training throughout the 16 week intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey Protein and RISE exercise routine
Description: Subjects will consume 20 grams of whey protein three times per day (total of 60 grams) and perform a combination of exercise involving functional resistance exercise (R); sprint intervals (I); stretching/pilates/yoga (S); and endurance exercise (E); RISE four days per week.
Study: NCT04037072

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Topical application of Normal Saline
Study: NCT01765855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betrixaban single oral dose
Study: NCT02584426

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic Distribution of Cefazolin
Study: NCT01375790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise with Whole-body vibration platform
Description: The participants will perform static/dynamic exercises (balance and resistance training) on a vibratory platform (Frequency: 30-35 Hz; Amplitude: 2-4 mm).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The participants will perform the same static/dynamic exercises (balance and resistance training) like WBV group but without the vibration stimuli.
Study: NCT02487680

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino Acids and chromium-picolinate containing drink
Description: Evaluation of the dietary supplement drink containing amino acids and chromium picolinate and aroma

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino Acids and chromium-picolinate containing drink
Description: Evaluation of the dietary supplement drink containing amino acids and chromium picolinate and aroma

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo drink
Description: Evaluation of the placebo supplement drink containing only aroma

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo drink
Description: Evaluation of the placebo supplement drink containing only aroma
Study: NCT04045353

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low carbohydrate diet education
Description: A 200 page informational document that connects with an online application will be provided to subjects.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low carbohydrate diet education
Description: A 200 page informational document that connects with an online application will be provided to subjects.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low carbohydrate diet education with behavioral component
Description: A 12 week course taught be a certified instructor will teach subjects about a low carbohydrate document. Subjects will also be given a 200 page informational document that connects with an online application.
Study: NCT03278691

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 1 ml saline IV Q6H

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 15 mg (15 mg/ml) IV Q6H
Study: NCT03149796

Intervention type: OTHER
Intervention: laboratory blood tests
Description: Serum concentrations of leptin, adiponectin, resistin, interleukin-6 and high sensitivity C reactive protein were measured by ELISA in both study groups

Intervention type: OTHER
Intervention: laboratory blood tests
Description: Serum concentrations of leptin, adiponectin, resistin, interleukin-6 and high sensitivity C reactive protein were measured by ELISA in both study groups
Study: NCT02068612

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Training+Interval Training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity Continuous Training
Study: NCT02569918

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surface electrical stimulation
Description: Surface electrical stimulation using the following experimental devices. 1) The CE-approved HASOMED electrical isolated stimulator (Rehastim). 2) Two hand prosthesis: the robotic hand Azzurra (Prensilia, Italy) and the robotic hand Multi-sensory Prosthetic Hand (Wessling robotics, Germany) 3) The EPIONE Psychophysical Testing Platform software for stimulator control. Surface stimulation therapy is provided while providing visual guidance to the subject.
Study: NCT02033031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis intravitreal injection
Description: Lucentis intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin intravitreal injection
Description: Avastin intravitreal injection
Study: NCT02773602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 200 μgm/kg of dexamethasone in 1 ml saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: 2 μg/kg of clonidine in 1 ml saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 1 ml of saline added to the ropivacaine, 0.2%, 1 ml/kg
Study: NCT02203409

Intervention type: PROCEDURE
Intervention: Laparoscopic ALPPS
Description: Laparoscopic Associating Liver Partition and Portal Vein Ligation for Two-stage Hepatectomy